Back to search

Article

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of <i>BRAF</i> / <i>NRAS</i> Status

2025-07-08

Abstract excerpt

“Pro-senescence therapy”, which triggers both permanent cell cycle arrest and an immune response, has been proposed as a strategy for cancer treatment, but is still controversial. To assess this strategy in melanoma, we performed a high throughput microscopy-based senescence screen utilizing a panel of melanoma cell lines with different driver mutations and a collection of clinical and experimental drugs. We found...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cdf029ba-3a0c-5f61-a544-56200553991a
DOI
10.1101/2025.07.04.663080
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of <i>BRAF</i> / <i>NRAS</i> StatusDOI 10.1101/2025.07.04.663080
Select a neighboring publication to make it the new centre.